8-K: Applied Therapeutics Reports Q1 2024 Results, Govorestat Regulatory Progress Highlighted

Applied Therapeutics announced its first quarter 2024 financial results, highlighting regulatory advancements for govorestat and progress in other clinical programs.

Summary

• Applied Therapeutics reported its financial results for the first quarter of 2024, ending March 31.
• The company's cash and cash equivalents totaled $146.5 million, a significant increase from $49.9 million at the end of 2023.
• Research and development expenses decreased to $12.2 million from $15.9 million in the same quarter of the previous year.
• General and administrative expenses increased to $9.1 million from $5.6 million year-over-year.
• The net loss for the quarter was $83.9 million, or $0.67 per share, compared to a net loss of $10.1 million, or $0.18 per share, in the first quarter of 2023.
• The company expects its current cash reserves to fund operations into 2026.
• A potential sale of a priority review voucher (PRV) upon govorestat approval could further extend the cash runway.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive regulatory progress and clinical trial results offset by a significant increase in net loss and a delay in the EMA decision. The company's strong cash position and potential for a PRV sale are positive, but the increased expenses and net loss temper the overall sentiment.

Positives

• The company has made significant regulatory progress with govorestat, including priority review status from the FDA and ongoing review by the EMA.
• The appointment of a Chief Commercial Officer indicates a strong focus on the upcoming commercial launch of govorestat.
• The Phase 3 ARISE-HF study showed positive results for AT-001 in diabetic cardiomyopathy, demonstrating a statistically significant difference in cardiac functional capacity in a subgroup of patients and prevention of progression to overt heart failure.
• The company's cash position has significantly improved, providing a runway into 2026.
• The potential sale of a priority review voucher could further extend the company's cash runway.

Negatives

• The company experienced a substantial net loss of $83.9 million in the first quarter of 2024, compared to a $10.1 million loss in the same period last year.
• General and administrative expenses increased significantly, primarily due to legal, professional, and commercialization costs.
• The EMA granted a 3-month extension to the Day 120 clock stop period, delaying the expected decision to early Q1 2025.

Risks

• The company's future success is dependent on the approval of its drug candidates by regulatory agencies.
• There are risks associated with the commercial launch of govorestat, including market acceptance and competition.
• The company's financial performance is subject to fluctuations in research and development expenses and other operating costs.
• The company's ability to fund its operations is dependent on its cash reserves and potential future financing.

Future Outlook

The company anticipates its current cash reserves will fund operations into 2026, with a potential extension from the sale of a priority review voucher. They are also focused on the potential approval and commercial launch of govorestat and advancing other pipeline programs.

Management Comments

• Preparations are underway for the potential approval and commercial launch of govorestat for the treatment of Classic Galactosemia in the US and EU, following the significant regulatory progress we have already made in 2024, said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics.
• We are also discussing a potential NDA submission for SORD Deficiency with the Neurology Division at FDA, further advancing our objective of bringing first ever treatment to patients with rare diseases.

Industry Context

This announcement reflects the ongoing trend in the biopharmaceutical industry of focusing on rare diseases with high unmet medical needs. The regulatory progress of govorestat and the positive clinical data for AT-001 are significant milestones for Applied Therapeutics in a competitive landscape.

Comparison to Industry Standards

• The increase in cash reserves from $49.9 million to $146.5 million is a positive sign, indicating successful fundraising or strategic financial management, which is crucial for biotech companies in the clinical stage.
• The decrease in R&D expenses from $15.9 million to $12.2 million could be due to the completion of certain clinical trials or a shift in focus, which is not uncommon in the industry.
• The increase in G&A expenses from $5.6 million to $9.1 million is likely due to the company's preparations for the potential commercial launch of govorestat, which is a typical pattern for companies approaching product approval.
• The net loss of $83.9 million is substantial, but not unusual for a clinical-stage biotech company that is investing heavily in R&D and commercialization efforts. Companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics Inc. have also reported significant losses during their development phases.
• The PDUFA target action date of November 28, 2024, for govorestat is a critical milestone, and the priority review status is a positive indicator. This is comparable to other companies that have received priority review for their rare disease treatments, such as Ultragenyx Pharmaceutical Inc.
• The EMA's review of the govorestat MAA and the 3-month extension are standard procedures in the regulatory process, similar to what other companies like Vertex Pharmaceuticals have experienced with their European submissions.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the regulatory progress and potential for future revenue.
• Employees may be impacted by the company's growth and commercialization efforts.
• Patients with Classic Galactosemia and SORD Deficiency may benefit from the potential approval of govorestat.
• The company's suppliers and partners may see increased business opportunities as the company moves closer to commercialization.

Next Steps

• The company will continue preparations for the potential commercial launch of govorestat.
• They will continue discussions with the FDA regarding a potential NDA submission for govorestat for SORD Deficiency.
• The company will await the FDA's decision on the govorestat NDA by the PDUFA target action date of November 28, 2024.
• They will also await the EMA's decision on the govorestat MAA, expected in early Q1 2025.

Key Dates

Keywords

Govorestat, Galactosemia, SORD Deficiency, AT-001, Diabetic Cardiomyopathy, FDA, EMA, PDUFA, MAA, Clinical Trials, Biopharmaceutical, Rare Diseases, Priority Review, Commercialization